On Thursday, April 12 an FDA advisory panel will discuss
whether or not to recommend that the FDA approve Merck & Co’s COX-2
inhibitor, Arcoxia (etoricoxib). The drug is manufactured by Merck, the
same company that made Vioxx, which was pulled from the market in the fall of
2004. Merck applied for approval to sell Arcoxia... Read more
Health and finance media outlets are abuzz this week after a jury in New Jersey found that in the case of a Mr. Humeston of Idaho, Merck was intentionally and recklessly negligent in failing to provide adequate warning of the risks of taking Vioxx in the drug's package inserts. The jury also found that Vioxx contributed... Read more
Scientists studying genetic links to autoimmune disorders have made the news again this week with research linking 30 genes to autoimmune disorders such as rheumatoid arthritis, lupus and others. Newsweek published an interview this week online with two of the researchers from MIT’s Whitehead Institute. The scientists hope that the... Read more
A recent article in the online December issue of Arthritis & Rheumatism compared the effectiveness of two different types of Internet-based physical activity interventions for people with rheumatoid arthritis. In this study from the Netherlands, 160 patients were monitored over a period of a year. The patients were divided into two groups... Read more
A recent study may provide hope that scientists will one day be able to develop COX-2 inhibitor drugs, such as Celebrex and Vioxx, that do not have the associated risk of heart attacks and strokes. The research, published in the December issue of the Federation of American Societies for Experimental Biology (FASEB), found that Vioxx and the... Read more